Please login to the form below

Not currently logged in
Email:
Password:

Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

He will be the US biopharma's chairman of board of directors

Alzheon Jean-Pierre GarnierFormer GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage biopharmaceutical company Alzheon.

The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease.

Alzheon's founder, president and chief executive officer Martin Tolar said: “JP will provide invaluable insights and guidance as we advance our lead oral amyloid aggregation inhibitor, ALZ-801, into a phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”

Garnier served as SmithKline Beecham's chief executive officer, having joined the company in 1990 as president of pharmaceuticals for North America.

He subsequently became GSK's first CEO following its formation from the merger of Glaxo Wellcome and SmithKline Beecham in 2001 and he held that position until in 2008.

Garnier then became chief executive officer of Pierre Fabre Laboratories and chairman of biotechnology company Cerenis.

He is currently chairman of the board of directors for Swiss biopharmaceutical company Actelion.

11th December 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics